BR112023002733A2 - Composições e métodos de fabricação de células t - Google Patents
Composições e métodos de fabricação de células tInfo
- Publication number
- BR112023002733A2 BR112023002733A2 BR112023002733A BR112023002733A BR112023002733A2 BR 112023002733 A2 BR112023002733 A2 BR 112023002733A2 BR 112023002733 A BR112023002733 A BR 112023002733A BR 112023002733 A BR112023002733 A BR 112023002733A BR 112023002733 A2 BR112023002733 A2 BR 112023002733A2
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- manufacturing
- compositions
- methods
- specific
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000002659 cell therapy Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4253—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Moulding By Coating Moulds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Casting Or Compression Moulding Of Plastics Or The Like (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063065327P | 2020-08-13 | 2020-08-13 | |
| PCT/US2021/045800 WO2022036137A1 (en) | 2020-08-13 | 2021-08-12 | T cell manufacturing compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002733A2 true BR112023002733A2 (pt) | 2023-05-02 |
Family
ID=80248187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002733A BR112023002733A2 (pt) | 2020-08-13 | 2021-08-12 | Composições e métodos de fabricação de células t |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230374455A1 (https=) |
| EP (1) | EP4196135A4 (https=) |
| JP (1) | JP2023539056A (https=) |
| KR (1) | KR20230074719A (https=) |
| CN (1) | CN116710551A (https=) |
| AU (1) | AU2021325081A1 (https=) |
| BR (1) | BR112023002733A2 (https=) |
| CA (1) | CA3189285A1 (https=) |
| CL (1) | CL2023000437A1 (https=) |
| CO (1) | CO2023002953A2 (https=) |
| CU (1) | CU20230011A7 (https=) |
| IL (1) | IL300564A (https=) |
| MX (1) | MX2023001815A (https=) |
| WO (1) | WO2022036137A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202004116QA (en) | 2017-11-08 | 2020-06-29 | Biontech Us Inc | T cell manufacturing compositions and methods |
| CN119317705A (zh) * | 2022-02-15 | 2025-01-14 | 马克治疗公司 | 用于抗原特异性t细胞扩增的组合物和方法 |
| CA3254900A1 (en) * | 2022-03-30 | 2023-10-05 | Mdx Management Llc | COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS |
| WO2024260318A1 (zh) * | 2023-06-19 | 2024-12-26 | 苏州沙砾生物科技有限公司 | 一种肿瘤特异性细胞的富集方法和应用 |
| WO2025245488A2 (en) * | 2024-05-24 | 2025-11-27 | Biontech Us Inc. | Compositions and methods for t cell manufacturing and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| WO1994003205A1 (en) | 1992-08-07 | 1994-02-17 | Cytel Corporation | Hla binding peptides and their uses |
| BR9406652A (pt) | 1993-03-05 | 1996-09-10 | Cytel Corp | Composição |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP2569633B1 (en) | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| SG11202004116QA (en) * | 2017-11-08 | 2020-06-29 | Biontech Us Inc | T cell manufacturing compositions and methods |
| EP3844265A2 (en) * | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| AR118859A1 (es) * | 2019-05-08 | 2021-11-03 | Neon Therapeutics Inc | Composiciones y métodos de fabricación de células t |
-
2021
- 2021-08-12 MX MX2023001815A patent/MX2023001815A/es unknown
- 2021-08-12 AU AU2021325081A patent/AU2021325081A1/en active Pending
- 2021-08-12 BR BR112023002733A patent/BR112023002733A2/pt unknown
- 2021-08-12 US US18/007,024 patent/US20230374455A1/en active Pending
- 2021-08-12 IL IL300564A patent/IL300564A/en unknown
- 2021-08-12 CN CN202180070338.2A patent/CN116710551A/zh active Pending
- 2021-08-12 CU CU2023000011A patent/CU20230011A7/es unknown
- 2021-08-12 CA CA3189285A patent/CA3189285A1/en active Pending
- 2021-08-12 WO PCT/US2021/045800 patent/WO2022036137A1/en not_active Ceased
- 2021-08-12 KR KR1020237008593A patent/KR20230074719A/ko active Pending
- 2021-08-12 JP JP2023509799A patent/JP2023539056A/ja active Pending
- 2021-08-12 EP EP21856741.0A patent/EP4196135A4/en active Pending
-
2023
- 2023-02-10 CL CL2023000437A patent/CL2023000437A1/es unknown
- 2023-03-10 CO CONC2023/0002953A patent/CO2023002953A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023001815A (es) | 2023-04-11 |
| JP2023539056A (ja) | 2023-09-13 |
| IL300564A (en) | 2023-04-01 |
| AU2021325081A1 (en) | 2023-04-13 |
| EP4196135A4 (en) | 2024-08-21 |
| US20230374455A1 (en) | 2023-11-23 |
| EP4196135A1 (en) | 2023-06-21 |
| CU20230011A7 (es) | 2023-12-07 |
| CO2023002953A2 (es) | 2023-05-19 |
| CN116710551A (zh) | 2023-09-05 |
| CL2023000437A1 (es) | 2023-07-28 |
| KR20230074719A (ko) | 2023-05-31 |
| WO2022036137A1 (en) | 2022-02-17 |
| CA3189285A1 (en) | 2022-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022363A2 (pt) | Composições e métodos para fabricação de células t | |
| BR112023002733A2 (pt) | Composições e métodos de fabricação de células t | |
| MX2023006997A (es) | Alcaloides de indol modificados para usos terapeuticos. | |
| Grant et al. | Proton versus conventional radiotherapy for pediatric salivary gland tumors: acute toxicity and dosimetric characteristics | |
| BR112021018627A2 (pt) | Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia | |
| MX2022003466A (es) | Interrupción de los tejidos tumorales al dirigir la proteína de activación de fibroblastos (fap). | |
| BR112022001148A2 (pt) | Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto | |
| MX2020009773A (es) | Terapia de combinacion. | |
| BR112019022901A2 (pt) | precursor de linhagem mesenquimal ou células t com imunossupressão intensificada | |
| AR109707A1 (es) | Generación y uso en inmunoterapia adoptiva de células t de memoria tipo células madre | |
| BR112021024946A2 (pt) | Célula de mamífero, método para produzir uma célula de mamífero implantável, e, uso de uma célula de mamífero | |
| BR112023002453A2 (pt) | Composições de agente de via de estresse de replicação e métodos para tratar câncer | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| BR112023020669A2 (pt) | Terapias de combinação para o tratamento de câncer | |
| MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
| MX2021015403A (es) | Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario. | |
| MX2024001269A (es) | Inhibidores de rock2 y sus usos. | |
| MX2025010922A (es) | Anticuerpo que se une especificamente a claudin18.2, y metodo de preparacion para este y aplicacion de este | |
| BR112023020872A2 (pt) | Sistemas de tratamento, métodos para aumentar a taxa metabólica, reduzir gordura e melhorar um distúrbio de peso e uma ou mais doenças, bem como usos de uma fonte de energia para reduzir gordura, aumentar a taxa metabólica, melhorar um distúrbio de peso e/ou melhorar uma ou mais doenças | |
| Chen et al. | Recent advances in therapeutic modalities against breast cancer-related lymphedema: future epigenetic landscape | |
| WO2022002065A9 (zh) | 抗cd40抗体或抗原结合片段及其应用 | |
| MX2021001764A (es) | Terapia de combinacion. | |
| BR112022010345A2 (pt) | Tratamento envolvendo células efectoras imune projetadas por receptores de antígeno | |
| MX2024012392A (es) | Terapia combinada para el tratamiento del cancer | |
| JOP20250002A1 (ar) | مستقبل مستضد كيميري يشتمل على جسم نانوي bcma مرتبط بمجال تبادل إشارات داخل الخلايا كيميري |